Probiotix Health (FRA:X90) Tax Expense: €-0.00 Mil (TTM As of Dec. 2025)


What is Probiotix Health Tax Expense?

Probiotix Health FRA:X90 Tax Expense is €-0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Probiotix Health's tax expense for the months ended in Dec. 2025 was €0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.00 Mil.


Probiotix Health  (FRA:X90) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Probiotix Health Tax Expense Related Terms


Probiotix Health Tax Expense Historical Data

* Premium members only.

The historical data trend for Probiotix Health's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Probiotix Health Tax Expense Chart

Probiotix Health Annual Data
Trend Dec18 Dec19 Dec20 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial 0.00 0.00 -0.02 -0.01 -0.00

Probiotix Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 0.00 -0.00 0.00

Probiotix Health Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of €-0.00 Mil mean?
Probiotix Health (FRA:X90) has a Tax Expense of €-0.00 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Probiotix Health and its competitors.
Is Probiotix Health's Tax Expense too high?
Probiotix Health's current Tax Expense is €-0.00 Mil.
How does Probiotix Health's Tax Expense compare to VRTX and REGN?
Probiotix Health's Tax Expense of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Probiotix Health and its competitors. Probiotix Health's current Tax Expense is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Probiotix Health (FRA:X90) has a current Tax Expense of €-0.00 Mil. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 25.5% below its estimated fair value. The current Tax Expense is €-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Probiotix Health (FRA:X90), the current Tax Expense is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Probiotix Health Business Description

Other Exchanges PBX:UK
Address Nostell Business Estate, First Floor Zucchi Suite, Wakefield, GBR, WF4 1AB
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.